
ImmunityBio (IBRX) Stock Forecast & Price Target
ImmunityBio (IBRX) Analyst Ratings
Bulls say
ImmunityBio reported a significant 21% increase in Q4 2024 net product revenue to $7.2 million, driven by accelerating sales of its product candidate ANKTIVA following FDA approval. The company demonstrates strong clinical efficacy with a durable disease-free survival rate of 51.1% and ongoing improvements in complete response rates, highlighting the potential for ANKTIVA's application in treating non-muscle invasive bladder cancer. Additionally, strategic collaborations, such as with the Serum Institute of India, alongside successful submissions for regulatory approvals in Europe, position ImmunityBio for substantial revenue growth projected to reach $137.4 million by 2025 and $4.3 billion by 2034.
Bears say
ImmunityBio has consistently reported operating losses since its inception, indicating a potential struggle to achieve profitability in the foreseeable future. The company's financial flexibility is further hampered by its debt and revenue interest liabilities, which could adversely affect cash flows and limit opportunities for raising additional capital. Additionally, regulatory approval challenges and declining response rates for its therapies may contribute to investor skepticism, exacerbating negative sentiment surrounding the stock.
This aggregate rating is based on analysts' research of ImmunityBio and is not a guaranteed prediction by Public.com or investment advice.
ImmunityBio (IBRX) Analyst Forecast & Price Prediction
Start investing in ImmunityBio (IBRX)
Order type
Buy in
Order amount
Est. shares
0 shares